France
· Delayed Price · Currency is EUR Nicox Company Description
Nicox S.A. operates as an ophthalmology company in France and internationally.
The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation.
In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis.
Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
| Country | France |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Gavin Spencer |
Contact Details
Address: Sundesk Sophia Antipolis Valbonne, 06410 France | |
| Phone | 33 4 97 24 53 00 |
| Website | nicox.com |
Stock Details
| Ticker Symbol | ALCOX |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gavin M. Spencer | Chief Executive Officer and Director |
| Sandrine Gestin | Vice President of Finance and Human Resources |
| Doug Hubatsch | Executive Vice President and Chief Scientific Officer |
| Dr. Ramesh Krishnamoorthy | Senior Director and Head of Late Stage CMC and Quality Control |
| Dr. Jose Boyer | Consultant |